Genetic Technologies Limited

DB:DU8 Stock Report

Market Cap: €3.4m

Genetic Technologies Management

Management criteria checks 3/4

We currently do not have sufficient information about the CEO.

Key information

Kevin Camilleri

Chief executive officer

AU$296.1k

Total compensation

CEO salary percentage87.0%
CEO tenure3.3yrs
CEO ownershipn/a
Management average tenure3.3yrs
Board average tenure5yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Kevin Camilleri's remuneration changed compared to Genetic Technologies's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024AU$296kAU$258k

-AU$12m

Mar 31 2024n/an/a

-AU$12m

Dec 31 2023n/an/a

-AU$13m

Sep 30 2023n/an/a

-AU$12m

Jun 30 2023AU$281kAU$233k

-AU$12m

Mar 31 2023n/an/a

-AU$10m

Dec 31 2022n/an/a

-AU$9m

Sep 30 2022n/an/a

-AU$8m

Jun 30 2022AU$285kAU$212k

-AU$7m

Compensation vs Market: Kevin's total compensation ($USD184.57K) is below average for companies of similar size in the German market ($USD467.65K).

Compensation vs Earnings: Kevin's compensation has increased whilst the company is unprofitable.


CEO

Kevin Camilleri (47 yo)

3.3yrs

Tenure

AU$296,120

Compensation

Mr. Kevin Camilleri serves as Chief Executive Officer of EasyDNA at Genetic Technologies Limited since August 16, 2021. Mr. Camilleri joined the Genetic Technologies Limited in 2021. He has been Chief Oper...


Leadership Team

NamePositionTenureCompensationOwnership
Kevin Camilleri
Chief Executive Officer of EasyDNA3.3yrsAU$296.12kno data
Mark Ziirsen
CFO & Company Secretaryless than a yearno datano data
Paul Keith Viney
Consultant5.4yrsAU$180.45kno data
Erika Spaeth
Director of Clinical & Scientific Affairsno datano datano data

3.3yrs

Average Tenure

Experienced Management: DU8's management team is considered experienced (3.3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Lindsay Wakefield
Independent Non-Executive Director10.3yrsAU$74.88k0.065%
€ 2.2k
Peter Rubinstein
Independent Non-Executive Chairman6.9yrsAU$150.19k2.54%
€ 86.4k
Jerzy Muchnicki
Non-Independent Non-Executive Director6.9yrsAU$87.44k1.55%
€ 52.6k
Finlay Macrae
Member of Scientific & Medical Advisory Board3.1yrsno datano data
Jon Emery
Member of Scientific & Medical Advisory Board3.1yrsno datano data
Ora Gordon
Member of Scientific & Medical Advisory Board3.1yrsno datano data

5.0yrs

Average Tenure

66yo

Average Age

Experienced Board: DU8's board of directors are considered experienced (5 years average tenure).


Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/25 12:43
End of Day Share Price 2024/10/16 00:00
Earnings2024/06/30
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Genetic Technologies Limited is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Marc KennisAPP Securities Pty Ltd.
Kevin DeGeeterLadenburg Thalmann & Company
Chris KallosMST Financial Services Pty Limited